Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX)

$4.08 0.38 (10.27 %)
(As of 12/11/2017 02:25 AM ET)
Previous Close$3.70
Today's Range$3.60 - $4.15
52-Week Range$0.88 - $4.15
Volume3.03 million shs
Average Volume399,987 shs
Market Capitalization$137.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Debt-to-Equity RatioN/A
Current Ratio1.20%
Quick Ratio1.20%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.40 per share
Price / Book10.20

Profitability

Trailing EPS($0.84)
Net Income$-14,730,000.00
Net MarginsN/A
Return on Equity-330.42%
Return on Assets-144.29%

Miscellaneous

Employees12
Outstanding Shares33,630,000

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. View Viking Therapeutics' Earnings History.

Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2017?

3 equities research analysts have issued 1 year target prices for Viking Therapeutics' shares. Their predictions range from $6.00 to $8.00. On average, they anticipate Viking Therapeutics' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Viking Therapeutics.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:

  • Lawson Macartney Ph.D., Chairman of the Board
  • Brian W. Lian Ph.D., President, Chief Executive Officer, Director
  • , Bio & Compensation - 
  • Michael Morneau, Chief Financial Officer
  • Amy Broidrick, Senior Vice President - Corporate Development
  • , Bio & Compensation - 
  • Gregory S. Zante CPA, Vice President - Finance and Operations
  • Catherine Lee Kelleher M.D., Vice President - Clinical Development
  • , Bio & Compensation - 
  • Matthew W. Foehr, Director
  • Charles A. Rowland Jr., Director
  • Matthew Singleton, Independent Director
  • , Bio & Compensation - 
  • Stephen W. Webster, Independent Director

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Who owns Viking Therapeutics stock?

Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (1.02%) and Citadel Advisors LLC (0.20%). View Institutional Ownership Trends for Viking Therapeutics.

Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?

Viking Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Citadel Advisors LLC. View Insider Buying and Selling for Viking Therapeutics.

How do I buy Viking Therapeutics stock?

Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of Viking Therapeutics stock can currently be purchased for approximately $4.08.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $137.21 million. The biotechnology company earns $-14,730,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Viking Therapeutics employs 12 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (VKTX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Viking Therapeutics (NASDAQ:VKTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.75$7.33$7.33$6.67
Price Target Upside: 187.04% upside234.86% upside521.47% upside429.10% upside

Viking Therapeutics (NASDAQ:VKTX) Consensus Price Target History

Price Target History for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017Roth CapitalSet Price TargetBuy$6.00HighView Rating Details
11/28/2017Maxim GroupSet Price TargetBuy$5.00 -> $8.00HighView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy -> Buy$7.00N/AView Rating Details
8/11/2016LaidlawLower Price TargetBuy$20.00 -> $10.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Viking Therapeutics (NASDAQ:VKTX) Earnings History and Estimates Chart

Earnings by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ VKTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.19)($0.22)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.21)ViewListenView Earnings Details
3/21/2017Q4 2016($0.20)($0.18)ViewN/AView Earnings Details
11/10/2016Q316($0.21)($0.20)ViewN/AView Earnings Details
8/10/2016Q2($0.20)($0.22)ViewN/AView Earnings Details
5/10/2016Q1($0.45)($0.40)ViewN/AView Earnings Details
3/8/2016Q415($0.44)($0.56)ViewN/AView Earnings Details
11/5/2015($0.37)($0.53)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($1.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Viking Therapeutics (NASDAQ:VKTX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.20)($0.20)($0.20)
Q3 20172($0.20)($0.19)($0.20)
Q4 20172($0.19)($0.17)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Viking Therapeutics (NASDAQ:VKTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 7.50%
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ VKTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Matthew W FoehrDirectorBuy13,000$1.21$15,730.00View SEC Filing  
4/13/2016Matthew W FoehrDirectorBuy20,000$1.24$24,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Viking Therapeutics (NASDAQ VKTX) News Headlines

Source:
DateHeadline
 Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share Brokerages Expect Viking Therapeutics, Inc. (VKTX) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - December 9 at 9:08 PM
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/ShViking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh
www.streetinsider.com - December 7 at 4:39 PM
Viking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh - StreetInsider.comViking Therapeutics (VKTX) Prices 5.13M Share Offering at $2.50/Sh - StreetInsider.com
www.streetinsider.com - December 7 at 10:57 AM
MacroGenics (MGNX) & Viking Therapeutics (VKTX) Head-To-Head ContrastMacroGenics (MGNX) & Viking Therapeutics (VKTX) Head-To-Head Contrast
www.americanbankingnews.com - December 6 at 5:30 PM
Viking Therapeutics (VKTX) Plans Public Offering of Common StockViking Therapeutics (VKTX) Plans Public Offering of Common Stock
www.streetinsider.com - December 6 at 10:50 AM
Viking Therapeutics Announces Proposed Public Offering of Common StockViking Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 5 at 4:21 PM
Viking Therapeutics: Buy The Rumor, Buy The News - Seeking AlphaViking Therapeutics: Buy The Rumor, Buy The News - Seeking Alpha
seekingalpha.com - December 2 at 8:49 AM
ValuEngine Downgrades Viking Therapeutics (VKTX) to SellValuEngine Downgrades Viking Therapeutics (VKTX) to Sell
www.americanbankingnews.com - December 2 at 12:40 AM
Roth Capital Analysts Give Viking Therapeutics (VKTX) a $6.00 Price TargetRoth Capital Analysts Give Viking Therapeutics (VKTX) a $6.00 Price Target
www.americanbankingnews.com - November 30 at 9:54 AM
Zacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Viking Therapeutics, Inc. (VKTX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 30 at 1:28 AM
Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatmentViking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment
www.marketwatch.com - November 29 at 10:39 AM
Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211
www.streetinsider.com - November 29 at 10:39 AM
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip FractureViking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
www.prnewswire.com - November 29 at 10:39 AM
VKTX: Positive Results From Phase 2 Study of VK5211 in Hip FractureVKTX: Positive Results From Phase 2 Study of VK5211 in Hip Fracture
finance.yahoo.com - November 29 at 10:39 AM
Contrasting Viking Therapeutics (VKTX) & Its PeersContrasting Viking Therapeutics (VKTX) & Its Peers
www.americanbankingnews.com - November 28 at 3:06 PM
Viking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211 - StreetInsider.comViking Therapeutics (VKTX) Reports Positive Top-Line Results from Phase 2 Study of VK5211 - StreetInsider.com
www.streetinsider.com - November 28 at 11:36 AM
Viking Therapeutics (VKTX) PT Set at $8.00 by Maxim GroupViking Therapeutics (VKTX) PT Set at $8.00 by Maxim Group
www.americanbankingnews.com - November 28 at 11:20 AM
Analyzing Viking Therapeutics (VKTX) and Its PeersAnalyzing Viking Therapeutics (VKTX) and Its Peers
www.americanbankingnews.com - November 27 at 3:56 PM
Head-To-Head Comparison: Viking Therapeutics (VKTX) and Its RivalsHead-To-Head Comparison: Viking Therapeutics (VKTX) and Its Rivals
www.americanbankingnews.com - November 24 at 1:24 AM
Viking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth CapitalViking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth Capital
www.americanbankingnews.com - November 21 at 10:33 AM
Viking Therapeutics (VKTX) vs. Its Rivals Head-To-Head AnalysisViking Therapeutics (VKTX) vs. Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - November 14 at 9:48 AM
Viking Therapeutics (VKTX) Buy Rating Reaffirmed at HC WainwrightViking Therapeutics' (VKTX) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 12 at 1:10 PM
VKTX: Data From Phase 2 Trial of VK5211 to be Reported SoonVKTX: Data From Phase 2 Trial of VK5211 to be Reported Soon
finance.yahoo.com - November 12 at 1:10 PM
Viking Therapeutics, Inc. (VKTX) Announces Quarterly  Earnings ResultsViking Therapeutics, Inc. (VKTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 5:36 PM
Viking Therapeutics (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking AlphaViking Therapeutics' (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - November 9 at 9:32 AM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateViking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 9:32 AM
Analyzing Viking Therapeutics (VKTX) and The CompetitionAnalyzing Viking Therapeutics (VKTX) and The Competition
www.americanbankingnews.com - November 8 at 9:34 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)
www.prnewswire.com - November 1 at 10:25 AM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
finance.yahoo.com - November 1 at 10:25 AM
Viking Therapeutics, Inc. (VKTX) Set to Announce Quarterly Earnings on WednesdayViking Therapeutics, Inc. (VKTX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Analyzing Viking Therapeutics (VKTX) and Its CompetitorsAnalyzing Viking Therapeutics (VKTX) and Its Competitors
www.americanbankingnews.com - November 1 at 1:20 AM
Viking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts TargetViking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts Target
finance.yahoo.com - October 31 at 11:48 AM
VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both CompoundsVKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds
finance.yahoo.com - October 28 at 7:51 AM
Viking Therapeutics (VKTX) Announces Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked ... - StreetInsider.comViking Therapeutics (VKTX) Announces Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked ... - StreetInsider.com
www.streetinsider.com - October 24 at 4:16 PM
Viking Therapeutics (VKTX) Announces Results from In Vivo Study of VK2809 - StreetInsider.comViking Therapeutics (VKTX) Announces Results from In Vivo Study of VK2809 - StreetInsider.com
www.streetinsider.com - October 24 at 4:16 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
finance.yahoo.com - October 24 at 12:05 PM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid AssociationViking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 23 at 8:56 AM
Viking Therapeutics: What Direction Now For This ~$2.50 Biotech Busted IPO? - Seeking AlphaViking Therapeutics: What Direction Now For This ~$2.50 Biotech 'Busted IPO'? - Seeking Alpha
seekingalpha.com - October 20 at 9:59 AM
Health Care Sector Update for 10/18/2017: VKTX,SPPI,AKTX - NasdaqHealth Care Sector Update for 10/18/2017: VKTX,SPPI,AKTX - Nasdaq
www.nasdaq.com - October 18 at 9:09 PM
VKTX: KOLs Highlight Necessity For Effective Hip Fracture TreatmentVKTX: KOLs Highlight Necessity For Effective Hip Fracture Treatment
finance.yahoo.com - October 12 at 9:51 AM
Viking Therapeutics, Inc. (VKTX) Given "Buy" Rating at Maxim GroupViking Therapeutics, Inc. (VKTX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - October 5 at 2:56 PM
Viking Therapeutics (VKTX) Reports Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-ALD - StreetInsider.comViking Therapeutics (VKTX) Reports Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-ALD - StreetInsider.com
www.streetinsider.com - October 4 at 8:52 AM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
finance.yahoo.com - October 4 at 8:52 AM
Corporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park CapitalCorporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park Capital
finance.yahoo.com - October 3 at 2:33 PM
Should You Buy Viking Therapeutics Inc (VKTX) Now?Should You Buy Viking Therapeutics Inc (VKTX) Now?
finance.yahoo.com - September 23 at 10:48 AM
Viking Therapeutics (VKTX) Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in NASH - StreetInsider.comViking Therapeutics (VKTX) Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in NASH - StreetInsider.com
www.streetinsider.com - September 13 at 3:55 PM
VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASHVKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH
finance.yahoo.com - September 13 at 11:02 AM
Viking Therapeutics (VKTX) "Buy" Rating Reaffirmed at Maxim GroupViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - September 11 at 4:31 PM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
finance.yahoo.com - September 11 at 8:20 AM
Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809
www.streetinsider.com - September 8 at 9:59 AM

SEC Filings

Viking Therapeutics (NASDAQ:VKTX) SEC Filings

DateFilerForm TypeView
12/07/2017
3:38 PM
Viking Therapeutics (Filer)
Form 424B5
View Filing
12/06/2017
8:16 PM
Viking Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing

Social Media

Financials

Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Viking Therapeutics (NASDAQ VKTX) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.